Highlights
-
First patient received first dose in INSIGHT-004, a phase I clinical trial
-
Evaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indications
-
Patient recruitment for the trial is ongoing in Germany, with first data expected in 2019
For further information please download PDF attached:
Download this document
